Transendocardial Injection of Expanded Autologous CD34+ Cells After Myocardial Infarction: Results of the EXCELLENT Trial

Roncalli J, Roubille F, Cottin Y, Leroux L, Mathur A, Irving J, Khan S, Meneveau N, Bresson D, Hovasse T, Pompilio G, Matta A, Henon P, Trebuchet G, de Kalbermatten M, Garitaonandia I, Saloux E, Manrique A, Meyer N, Marie P-Y, Bhatt D, Solomon S,  Montalescot G,  Newby D, Zannad F, the EXCELLENT Trial Investigators

JACC: HEART FAILURE Volume 13, Issue 11, November 2025, 102626 | https://doi.org/10.1016/j.jchf.2025.102626

Design and Validation of an Automated Process for the Expansion of Peripheral Blood-Derived CD34+ Cells for Clinical Use After Myocardial Infarction.

Saucourt C, Vogt S, Merlin A, Valat C, Criquet A, Harmand L, Birebent B, Rouard H, Himmelspach C, Jeandidier É, Chartois-Leauté AG, Derenne S, Koehl L, Salem JE, Hulot JS, Tancredi C, Aries A, Judé S, Martel E, Richard S, Douay L, Hénon P.
Stem Cells Transl Med. 2019 Aug;8(8):822-832. doi: 10.1002/sctm.17-0277. Epub 2019 Apr 29. PMID: 31037857; PMCID: PMC6646685.